Vanda Pharmaceuticals | VNDA - Trade Debtors


Vanda Pharmaceuticals reported $47.1M in Trade Debtors for its fiscal quarter ending in December of 2024.





Trade Debtors Change Date
Acadia Pharmaceuticals USD 166.33M 17.95M Jun/2026
Agios Pharmaceuticals USD 16.13M 5.56M Mar/2026
Akebia Therapeutics USD 47.03M 19.19M Dec/2025
Alnylam Pharmaceuticals USD 912.74M 28.78M Jun/2026
Anika Therapeutics USD 29.33M 661K Dec/2025
Arrowhead Research USD 8.56M 7.13M Jun/2026
AstraZeneca USD 18.86B 972M Jun/2026
Bristol-Myers Squibb USD 13.83B 535M Jun/2026
Eli Lilly USD 23.48B 2.3B Jun/2026
Enanta Pharmaceuticals USD 40.16M 1.52M Dec/2024
Halozyme Therapeutics USD 453.33M 4.66M Jun/2026
Heron Therapeutics USD 89.59M 8.54M Dec/2025
Insmed USD 215.32M 36.77M Jun/2026
J&J USD 19.05B 3.49B Jun/2026
Lexicon Pharmaceuticals USD 2.38M 50K Dec/2025
Ligand Pharmaceuticals USD 54.8M 6.25M Mar/2026
Merck USD 12.21B 435M Mar/2026
Moderna USD 17M 54M Jun/2026
Novartis USD 9.6B 2.69B Mar/2026
Pfizer USD 16.19B 19M Jun/2026
PTC Therapeutics USD 219.92M 38.3M Mar/2026
Puma Biotechnology USD 28.1M 3.52M Jun/2024
Sangamo BioSciences USD 581K 110K Jun/2024
Sanofi EUR 492M 10M Jun/2026
Takeda JPY 956.14B 79.79B Jun/2026
Teva Pharmaceutical Industries USD 3.49B 100M Jun/2026
Ultragenyx Pharmaceutical USD 60M 98M Mar/2026
Vanda Pharmaceuticals USD 47.1M 4.35M Dec/2024
Veracyte USD 54.18M 4.06M Jun/2026